bexarotene has been researched along with Hyperlipemia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Atigadda, VR; Boerma, LJ; Brouillette, WJ; Desphande, A; Grubbs, CJ; Lobo-Ruppert, S; Muccio, DD; Smith, CD; Xia, G | 1 |
| Zic, JA | 1 |
| Huen, AO; Kim, EJ | 1 |
| Garcia Morillo, JS; Muñiz Grijalvo, O; Pamies Andreu, E; Rodriguez Suarez, S | 1 |
| Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A | 1 |
| Alvarado, CS; Busam, KJ; Hale, GA; Horwitz, S; Jaffe, ES; Kim, YH; Mehta, N; Myskowski, P; Pulitzer, M; Wayne, AS; Zwerner, J | 1 |
| Assaf, C; Bagot, M; Dummer, R; Duvic, M; Gniadecki, R; Knobler, R; Ranki, A; Schwandt, P; Whittaker, S | 1 |
4 review(s) available for bexarotene and Hyperlipemia
| Article | Year |
|---|---|
Diagnosis and Management of Cutaneous Lymphomas Including Cutaneous T-cell Lymphoma.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Arthropods; Bexarotene; Bites and Stings; Brentuximab Vedotin; Diagnosis, Differential; Humans; Hyperlipidemias; Hypothyroidism; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Papulosis; Mycosis Fungoides; Peripheral Nervous System Diseases; Prognosis; Sezary Syndrome; Skin Diseases; Skin Neoplasms | 2021 |
The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Humans; Hyperlipidemias; Hypothyroidism; Immunologic Factors; Interferons; Mycosis Fungoides; PUVA Therapy; Retinoids; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2015 |
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Contraindications; Exanthema; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Incidental Findings; Kidney Neoplasms; Male; Middle Aged; Mycosis Fungoides; Neoplasms, Multiple Primary; Simvastatin; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2008 |
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Topics: Anticarcinogenic Agents; Bexarotene; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2006 |
3 other study(ies) available for bexarotene and Hyperlipemia
| Article | Year |
|---|---|
Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bexarotene; Binding Sites; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Crystallography, X-Ray; Fatty Acids, Unsaturated; Female; Humans; Hyperlipidemias; Mammary Neoplasms, Experimental; Models, Molecular; Molecular Structure; Naphthalenes; Rats; Retinoid X Receptor alpha; Stereoisomerism; Structure-Activity Relationship; Tetrahydronaphthalenes; Transcriptional Activation | 2014 |
[Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cholesterol, HDL; Combined Modality Therapy; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Male; Middle Aged; Mycosis Fungoides; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Salvage Therapy; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2016 |
Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Child; Child, Preschool; Diabetes Mellitus, Type 1; Disease-Free Survival; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Panniculitis; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Young Adult | 2012 |